WIZP News and Press, Wize Pharma Inc From 04/15/19

By Rena Sherbill Jonathan Liss and I covered the CannaTech conference in Tel Aviv that ran from April 1-2. We talked with a wide variety of attendees and presenters - from executives and scientists to venture capitalists, money managers, marketers and journalists. We'll be rel...

Cannabics Pharmaceuticals (OTCQB: CNBX ) is taking a unique approach in treating different types of cancers with its drug-screening tools and artificial intelligence (AI) platform to develop cannabinoid-based therapies that are more specific to a patient. Although the company is a publicly...

HOD HASHARON, Israel, March 11, 2019 /PRNewswire/ --  Wize Pharma, Inc.  ("Wize Pharma" or the "Company") (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that it was informed by Resdevco, LO2A licenso...

HOD HASHARON, Israel , March 6 , 2019  /PRNewswire/ -- Wize Pharma, Inc. ("Wize Pharma" or the "Company") (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that the Company closed a deal with C...

BETHESDA, Maryland and TEL AVIV, Israel, March 6, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has closed an agreement with Wize...

Cannabics Pharmaceuticals ( OTCQB:CNBX ) and Wize Pharma ( OTCQB:WIZP ) have agreed to form a joint venture  (JV) aimed at developing cannabinoid-based treatments for ophthalmic disorders, including dry eye disease. More news on: Cannabics Pharmaceuticals Inc., Wize Pharma, Inc., Hea...

HOD HASHARON, Israel, Feb. 7, 2019 /PRNewswire/ --  Wize Pharma, Inc.  ("Wize Pharma" or the "Company") (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that the Company has signed an agreem...

BETHESDA, Maryland and TEL AVIV, Israel, Feb. 7, 2019 /PRNewswire/ --   Cannabics Pharmaceuticals Inc.  (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has entered into agreement with W...